UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_________________________________________________________________

FORM 8-K

_________________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 116, 2025

_________________________________________________________________

C4 THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

_________________________________________________________________


Delaware	001-39567	47-5617627
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

490 Arsenal Way, Suite 120 Watertown, MA		02472
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 231-0700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

_________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

CCCC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 7.01 Regulation FD Disclosure.

On October 1, 2025, C4 Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company had entered into a clinical trial collaboration and supply agreement (the “Agreement”) with Pfizer Inc. (“Pfizer”). A copy of this press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 8.01 Other Events.

On October 116, 2025, ~~the~~C4 ~~Company~~Therapeutics, ~~announced~~Inc. ~~that~~(the it“Company”) ~~had~~posted ~~entered~~a ~~into~~presentation ~~the~~with ~~Agreement~~data ~~with~~from ~~Pfizer.~~its ~~Under~~Phase ~~the~~1 ~~terms~~clinical trial of ~~the~~cemsidomide ~~Agreement,~~in ~~Pfizer~~combination ~~will~~with ~~supply~~dexamethasone ~~elranatamab~~for ~~(ELREXFIO®),~~the atreatment ~~B-cell~~of ~~maturation~~relapsed/refractory ~~antigen~~multiple ~~CD3~~myeloma. ~~targeted~~The ~~bispecific~~presentation ~~antibody~~has ~~(BCMAxCD3~~been ~~bispecific),~~published to the ~~Company~~“Events ~~for~~& ~~its~~Presentations” ~~upcoming~~page ~~Phase~~of ~~1b trial evaluating~~ the ~~safety~~investor ~~and~~relations ~~tolerability~~section of ~~cemsidomide,~~the anCompany’s ~~IKZF1/3~~website ~~degrader,~~ and ~~dexamethasone~~is infor ~~combination~~use ~~with~~in ~~elranatamab~~meetings ~~as a second line or later therapy for patients~~ with ~~multiple myeloma. Pursuant to the Agreement~~investors, ~~Pfizer~~analysts ~~will~~and ~~supply~~others. ~~elranatamab~~The topresentation ~~the~~is ~~Company~~filed atas noExhibit ~~cost~~99.1 ~~in exchange for access~~ to ~~data~~this ~~from~~Current ~~the~~Report ~~trial,~~on ~~while~~Form ~~the~~8-K ~~Company will sponsor~~ and ~~conduct~~incorporated ~~the~~herein ~~trial~~by reference.

Sales Agreement with TD Securities (USA) LLC

Effective October 16, 2025, the Company terminated the sales agreement prospectus, dated November 13, 2024, related to the sale of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), from time to time pursuant to the Sales Agreement, dated October 31, 2024, by and between TD Securities (USA) LLC (“TD Cowen”) and the Company (the “Sales Agreement”). As a result, the Company will not make any sales of Common Stock pursuant to the Sales Agreement, unless and until a new sales agreement prospectus supplement or a new registration statement with sales agreement prospectus is filed. The Sales Agreement remains in full force and effect. As of June 30, 2025, the Company had issued and sold 3,769,483 shares of its Common Stock under the Sales Agreement with TD Cowen for gross proceeds of approximately $9.6 million, before deducting commissions to TD Cowen.

A copy of the Sales Agreement was filed as Exhibit 1.2 to the Company’s Registration Statement on Form S-3 (File No. 333-282933), which was originally filed with the SEC on October 31, 2024, and declared effective on November 13, 2024.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.

ExhibitNumber						Description
99.1						~~Press~~Data ~~release~~presentation ~~issued~~dated October 116, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	C4 Therapeutics, Inc.
Date: October 1, 2025	By:	/s/ Jolie M. Siegel
Date: October 16, 2025	By:	/s/ Jolie M. Siegel
		Jolie M. Siegel
		Chief Legal Officer and Secretary

Filing Compare · C4 Therapeutics, Inc.